As noted earlier, JMP Securities upgraded BioCryst to Outperform from Market Perform. Analyst Liisa Bayko believes that a trial of the company's BCX7353 drug for hereditary angioedema could indicate that the drug is capable of "significantly reducing, and possibly wiping out attacks." Bayko adds that "there is significant enthusiasm in the community for an oral option that can achieve at least a 50% reduction in attack frequency." Bayko thinks that the program has a 40% chance of success and could represent a market opportunity of about $12.9B. Target $10.